May 29, 2024 · Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease of the heart muscle. As it progresses, the heart can become unable to adequately …

ATTR-CM Discovery Initiative THE ISSUE Cardiac amyloidosis, including Transthyretin Amyloid Cardiomyopathy (ATTR-CM), is a serious and often underdiagnosed condition in which protein …

Mar 23, 2026 · Early recognition and diagnosis of ATTR-CM is critical, as timely care gives patients access to treatments that can extend survival, preserve physical function and maintain quality of life. …

May 27, 2025 · As part of this work, the Association today announced an initiative to improve education, outreach and access to clinical trials for gene editing therapies for transthyretin amyloid …

Video webinar series helps instructs healthcare professionals in improving care and treatment for patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Nov 22, 2024 · For instance, low QRS voltage on ECG is a late finding in cardiac amyloidosis present in fewer than half of people with biopsy-proven ATTR-CM, in contrast with earlier studies …

To join a gene editing trial, a person usually needs to meet certain requirements, such as: 1 Having a confirmed diagnosis of a genetic condition that affects the heart, like ATTR-CM 2 Having specific …

ATTR-CM: Severity & Relevance to Practice Diagnostic delays are common and diagnosis in ATTR-CM and diagnosis is often made at a more advanced stage

Jul 13, 2020 · The list of clinical clues and diagnostic testing provided in this quick reference guide are intended to promote earlier identification and accurate diagnosis of ATTR amyloidosis, with …

DALLAS, Nov. 3, 2025 — A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a non-invasive assessment tool may help identify …